

Lec 1...

pharmacodynamic - تأثير الدواء على الجسم -



Body -> constant
بالتالي ثابتا بلهجاتي
ال دوي ليعني احصل على
اثره ثابتا

pharmacokinetic: the study of how the body interacts with administered substances for the entire duration of exposure.

pharmacodynamic: the study of a drug's molecular, chemical & physiologic effects or action.

pharmacokinetics: (ADME)

- A: Absorption. امتصاص
- D: Distribution. توزيع
- M: Metabolism. ايض
- E: elimination. خروج



1. Absorption:

why? (oral dosage form) جديده انا بنهتم بـ
وخاصة اغلب الامراض: chronic
بهي باختصار ما رح يفتح اصل اعطى IV !! -

في 1 medicinal رح نركز على (oral)


now
بمر (solid drug) بمراحل وهي كالتالي: يتقلد

Disintegration -> Dissolution -> Absorption




* نتعامل مع ال (drug) :
functional group يعني رح اهتم بـ AS Chemical structure
إيش معنى هالحكي؟

functional group



لعتي يصير عندي Absorption فانا بحاجة لوجود كل من: (hydrophilic & hydrophobic) وأغلب أدويتنا بنلاتي فيها الشقين.

التوا لما يمر من (GIT) ويصير له امتصاص رح يمر عن طريق different transport processes



active carriers

هل وجدت ال(carriers) للأدوية؟ لا، هي موجودة لـ: *natural substrate*
 عتًا ال(*glucose*) بصرله امتصاص عن طريق ال(carriers)
 : *Amino acid*
 عتًا بجسمنا (20 aa) كلهم (L) ولا واحد (D) ...
 - (D) موجودين بس بالبكتيريا -


20 a-a

19 منهم *chiral* ← ذرة الكربون مرتبطة بأحزان مختلفة
 ← واحد منهم *A chiral*
 ↓ *glycine a-a*

* في الزمنات كان نبي دوا اسمه (Thalidomid) -
 ثاليدومايد - كانت توخده المرأة الحامل
 ب(1st trimester) عشان يقل symptoms ...
 بعد سنين وجدوا الأطفال ياي أمها قهص
 أخذوا هاد الدواء عندهم تشوهات ...
 والسبب *stereochemistry*
 تحولات الدواء ما بين ال (S) و (R) !
 ومن هنا تتضح أهمية *stereochemistry*

والفكرة هي كالتالي :
 ال (enzyme) مكون من شوي *amino acid*
 وهما عبارة عن *chiral* يعني تبعًا لهالحكي
 ال (enzyme) = *chiral* !
 وهو مسؤول عن (metabolism)
 فبالتالي قد يعمل *metabolism* لـ (X) ما يعمل
 لـ (Y) أو قد يعمل لـ (X و Y) !

* وملاحظة : *non-chiral = amino acid*
 بصيرلها امتصاص عن طريق ال(carriers) ...



: now

بنفس ال(membrane of GI tract) وجبوا *proteins* عاملة قناة بنسبها :
water channels

↳ it is very small in size

← لا تسمح بمرور أدويتنا

← (L) فقط بـستطيع العبور

مثلاً...

وحتى يستطيع *antibiotic* يقتل البكتيريا
water channels (gram -ve) لازم يمر من
 فأغلب الأدوية ياي بتشتغل على (G-ve) بتكون :
 * *Very hydrophilic* *

functional group:

① $CH_3CH_2CH_3-$: hydrophobic substituent
hydrophobic interaction
solubility **منخفضة**

② $COOH-$: polar ... H-bond
Carboxyl
H-bond interaction
good solubility

note:
* (carboxyl group): $COOH$
7.45
pH of blood > pKa of the drug that contains $COOH$
وهذا يعني رح يصير للدوا
ionized in the blood

③ * (amine): NH_2
ionized in stomach
pH of stomach < pKa of amine

now: why is ionization important?
pH partition hypothesis (theory) في
على أن نصتت
ionized form of the drug = hydrophilic
un-ionized form of the drug = hydrophobic

⇒ only un-ionized, non-polar drugs will penetrate a lipid membrane...




كيف في الدوا رح يصير له امتصاص من GIT
ورح يصير له distribution من خلال blood
ورح يصير له elimination & metabolism من
... Kidney & Liver
تفاهي

الدوا حتى يصير له امتصاص لازم يجبر
GIT membrane (Lipophilic) ...
بالتالي بهاي المرحلة أنا بحاجة إني يكون
دواي (hydrophobic) ...

مرحلة ما قبل الامتصاص ← (dissolution)
الدوا لازم يكون Soluble ...
↑ ionization ↑ solubility
↑ polar functional group ↑ solubility

بالدم أنا بحاجة إني (functional group) يعمل
interaction مع الألبومين (Albumin) ...
بجيت إذا الدوا ترشبت بالدم بعمل جلطة.

: in Liver •
The Liver is the main organ responsible
for drug metabolism.




so: the drug must be pass through
the Liver wall. (pass to hepatocyte)

* يعني لازم يكون ← hydrophobic
* وأيضًا لازم يصير ← interaction with
Liver enzyme

the result should be:
water soluble metabolite
(excretion) ...

: in Kidney •



ملاحظة: كل (membrane) في جسمنا هي نفس
(basic structure), الاختلاف الوحيد: porosity
مثلاً BBB إلا (porosity) قاعتها قليلة.

summary:

for drug ... we need to have a balance between:

Hydrophilic functional group & Hydrophobic functional group

(Totally hydrophobic) ما جدنا الدواء يكون لا يتولو كان هيك : تكون

(1) الال (solubility) رح تكون v. Low

(2) الال (absorption) رح تكون v. good

(3) في الدم ممكن يمسيره (precipitation)

(4) بالكد رح يجبر

جذ وصول الى رحلة الدواء بشكل سريع :

Blood → → Target



Interaction



response

← يؤثر (Chemical structure) على pharmacokinetic & pharmacodynamic

→ Drug interaction with Target

بحاجة لادئو يكون الدواء عنده

1. proper functional group.

2. proper size.

3. proper orientation.

ملحوظة: كل ما كان الدواء proper interaction كل ما احتجت منه dose اقل ...

ومش كل functional group بتدخل بال (interaction)



Introduction

→ physicochemical properties = biopharmaceutical properties

- The importance of physicochemical properties of the drug and the relationship of such properties to the pharmacological responses.
- Because these properties play an important role in * determining biological action of pharmaceuticals, it is appropriate to refer to these properties as **biopharmaceutical properties** of drug substances.
- Examples of such properties include solubility, partition coefficients, degree of ionization, and polymorphism, which in turn are *₂ determined by the chemical structure and stereochemistry of drug substances.


Introduction

- Drug molecules must cross various biological membranes and interact with intercellular and intracellular fluids before reaching the elusive region termed the “**site of action.**”
- Under these conditions, the biopharmaceutical properties of the drug must contribute favorably to facilitate absorption and distribution processes to ^{-زيادة-}augment the drug concentration at various active sites (Pharmacokinetics)

Introduction


- **Pharmacokinetics** may be simply defined as what the body does to the drug
- Pharmacokinetics is divided into several areas including the extent and ^①rate of absorption, ^②distribution, ^③metabolism and ^④excretion. This is commonly referred to as the ADME.

Identifying functional groups:




Examples:


PROBLEM #1




PROBLEM #2




PROBLEM #3




PROBLEM #4



PROBLEM #5




PROBLEM #6




omeprazole
acid reflux

PROBLEM #7




losartan
high blood pressure

PROBLEM #8



albuterol
asthma

the effect of chemical structure of the drug on Absorption...




* Ionization:

- depend on:

1. pH of biological system...
2. pKa of the drug

(بشكل عام ← pH ثابتة مع pKa صغيرة)



in stomach (acidic medium):


acidic drug = un-ionized form

☑ Absorption.

basic drug = ionized form.

☑ Absorption.

ملحوظة : قيمة الـ (pKa) ما بتخبرنا فيما لو كان الدواء (base or acid) ، لذلك بطالع بداية على functional group وبعديها بسني أفكاري عليها .



ملحوظة : بي تصنيف ثاني كالتالي :
strong pKa < 2
weak pKa: 2-10
very weak pKa > 10

← نفس الإشي بس مسمايات يعني (weak) نفسه (intermediate) و (v. weak) نفسه (weak) ...

acid : proton doner, e⁻ accepter
base : proton accepter, e⁻ doner




why HCl is strong while CH₃CH₂OH is not ?

كل ما كانت عندي (stable conjugated base) ... كل ما كان (strong acid)




إجبت الـ (-ve charge) على (O : good electronegative atom) لكننا مش لدرجة (Cl⁻) بالجداول الاتوري:




more stable conjugated base: لما (-ve charge) بتكون موجودة على (electronegative atom)

* (functional group) إذا شفتها بعرف إنو المركب عندي (strong acid) :

1. sulfonic acid



بتتوزع (e⁻) على (3 electrone. atoms)



طيب لو عندي :
pKa < 2
conjugated base
pKa 4-5
فإن :
e⁻ توزعت على (2 O) هون (3 O)

more acidic = ↓ pKa

كل ما كان الحمض أقوى رح يقدر يعمل (dissociation) أسرع ...

Base:

كذلك الأمر مع القاعدة ... كل ما كان عندي (stable conjugated acid) كل ما كانت (strong base).



* مين من بينهم stronger base?



why?

الإلكترونات هون موجودة على N بالمقابل ني الألايين (Aniline) الإلكترونات جزء من الوقت موجودين على N والجزء الثاني داخليين ب (resonance)

لازم الإلكترونات تكون Localized لحتى يكون strong base، لذا كل ما كانوا (e-) موجودين كان stronger base.

ملحوظة: بال (base) لحتى أعرف بنمسك ال (base) نفسه، لكن ني (acid) بنمسك ال (conjugated base) تاعته ...


نعود لموضوعنا ال Acid:

* (functional group) إذا شفتها بعرف إنو المركب عندي (strong acid):

1. sulfonic acid



2. phosphoric acid



- نفس الحكي -


3. sulfonamide

- conjugated with carbonyl group -




- N less electronegative than O- بالتالي لو بدني أقارنه ب (sulfonic acid) أو ب (phosphoric acid) يُعتبر weaker ...

ولو بدني أخليه أقوى بخفيف بدل H: carbonyl



4. carboxylic acid conjugated with carbonyl




* note: if carboxylic acid is conjugated with carbonyl group, it will be stronger.

- more stable conjugated base -

function group * إذا شفتها بعرف إنو
المركب strong base

1. Guanidine



* strong basic drug.
* pKa > 10
12

I: Ionized ✓

strong basic drug in stomach = ionized form.

pKa of drug > 10 & pH of stomach 3
pKa > pH ... ionized

strong acid & strong base = ionized throughout GIT

strong acid [I]⁻ } absorption
strong base [I]⁺ }

لكن:


وجدوا في أدوية إله (+ve charge) وصلها
... absorption

absorption -ve charge. ← مارح يصلها
+ve charge. ← ممكن

طيب ليش بعضي orally?
Local treatment ✓

يعني إذا أصلاً ما جدي يصيرله امتصاص
حتى يشتغل على GIT ...

(GlucoPhage - Metformin :)



hydrophilic group ✓
hydrophobic group X
Drug taken orally ✓

← طيب كيف؟ حاكينا لازم يكون
في الشقين.


...
strong basic drug → charge
→ ionized → absorption ✓

ممكن أعطي الدواء لشخصين، واحد يستجيب
والثاني لا... والسبب: الأول اختلف عن الثاني
بالا (carrier) ...

-ve protein = carrier*
والدوا +ve
بعلو (ion complexation)
وهيك بعبر الدواء.

← طبقاً مش كل (+ve) بربط معها هالحاي ٨٨


2. Amidine



* strong basic drug


intermediate (functional group)*

1. carboxylic acid. - acid-




← معلومة: الجسم ولا يمكن يعمل ionization
لا (OH) !
(very weak).

مشان هيل وجود (phenol) بالدوا
بساعد على امتصاصه.




2. Sulphonamide - acid-



: weak يعتبروا (functional group) *



1. Alcohol.
2. phenol.
3. Amides
4. Imides
5. Imidazole
6. pyrrole




pyrrole




وحدة من N رح تكون (e) ناعها داخلة بال (resonance) وحدة لا تكون (e) available




Imide



Amide



Imidazole



مش هين :


pyridine more basic than pyrrole...



all = basic drug

v. weak acid

phenol




Paracetamol

(analgesic and antipyretic)

- * unionized across the GIT ✓ absorption ✓
- * fulfilling all lipinski's rule of 5
- * 100 % Bioavailability

متاحة e available ؟

R: e⁻ donating more electro. ← N بتغني يعني available e




- الثاني -

(e⁻) متاحين مزة على N ومزة دلالا (resonance) ...

* بالتالي : الأول < الثاني - more basic -

- الثالث - (زي ال amine فوئاما)



Hybridization of N atom :

sp²

available good base

إذاهي إذاهي

→ Many drugs are either weak acids or weak bases in the largely aqueous environment of the body, meaning that they either donate or accept protons depending on the pH...

At neutral pH, weak acid tends to donate or lose a proton to become negatively ionized or charged, while a weak base tends to accept or gain a proton to become positively charged

This charge can influence a drug's absorption, its distribution between compartments, and its elimination from the body since a molecule which is charged whether positively or negatively will have a reduced ability to cross biological membranes by passive diffusion.

The proportion of drug that is ionized in a given compartment will depend on the pH of the compartment relative to the drug's pK_a ...

Many compartments have different pH:

- The stomach is acidic.
- The small intestine can be weakly basic.
- The blood has a pH of about 7.4
- The pH of urine in the kidney tubules & bladder can vary from acidic to basic.

At the low pH of the stomach, an acidic drug will be uncharged & may therefore be efficiently absorbed from this compartment.


on the other hand, a basic drug will accept a proton to become positively charged in the stomach & will therefore be poorly absorbed.

conversely, at the high pH of the small intestine, an acidic drug will be negatively charged & poorly absorbed, whereas a basic drug will be uncharged & therefore efficiently absorbed.

The Law of mass action covers the available drug that can leave a compartment... As the uncharged portion of the drug leaves the compartment, the number of charged molecules will decrease to maintain the balance of charged & uncharged molecules at the given pH.


clinically we can alter the pH of compartment to change the drug's degree of ionization in order to influence its ability to leave that compartment...

For example, in some instances of drug overdose, we can increase the pH of the fluid being filtered by the kidney by giving a solution of sodium lactate to sequester or trap on acidic drug in the urine, because it will be readily filtered by the kidney glomerulus. But in a compartment with a high pH, such as the tubule fluid of kidney, it will be more charged, and therefore reabsorption will be reduced from the renal tubule back into body. It is therefore more efficiently cleared from the body by excretion in the urine.




Aspirin

-carboxyl-



Furosemide



Methotrexate

•For aspirin and furosemide acid with pKa values of 3.5 and 3.9, the answer is that 99.99% of a given dose of drug will be ionised at the pH of blood or intracellular fluid.

•For methotrexate, the answer will be slightly less, but still greater than 99%

LIPINSKI'S RULES

(rule of five)

لعمري ليس خمسة بـ
كل الأرقام ياي
بتحكي فيها
من مشتقات
الرقم خمسة.

- molecular weight (g/mol) ≤ 500
- num. of H-bond acceptors ≤ 10
- num. of H-bond donors ≤ 5
- log P (lipophilicity) ≤ 5

MH
OH

exception
yes

- انتهاكات -

≥ 2 rule violations \rightarrow high risk of low solubility & membrane permeability

(1)
→ Lipinski's rules don't make a molecule more potent or have greater efficacy or lower toxicity.
Lipinski's rules are just about absorption...

→ Barriers to absorption:

1. solubility aqueous
2. permeability
3. first-pass effect.

① The molecule must dissolve at least a bit in either gastric fluid or intestinal fluid

Log p addresses this idea somewhat if a molecule has too high of a lipophilicity it won't be water soluble

② Drugs must cross membranes & membranes tend to be crossed passively by drugs...
They diffuse across the membranes... membranes are non-polar, so oral drugs need to not interact too strongly with water...
if the molecule binds water too tightly, the molecule will not enter the non-polar membrane, which is designed to block the movement of water.

H-bond donors & H-bond acceptors interact with water

These are intermolecular forces between the drug & water...

so, Lipinski's rules limit the number of H-bond donors & H-bond acceptors in the potential drug

② Another idea for permeability is size. Big molecules are slower to diffuse across a membrane, so the molecular weight is capped at 500

③ if a molecule undergoes extensive first-pass metabolism, it will have poor bioavailability & show low absorption into the central compartment. Lipinski's rules do nothing to prevent the first-pass effect or hepatic clearance...

if anything, keeping a molecule smaller makes the molecule a better possible fit into the active site of the metabolic enzymes.

Therefore, Lipinski's rules focus only on improving solubility & membrane permeability in order to maximize the oral absorption of a molecule.

Physiochemical Factors Affecting Drug Absorption Lipinski's rule of five


- Lipinski's rule of five
- As a rule of thumb, orally absorbed drugs tend to obey what is known as Lipinski's rule of five. The rule of five was derived from an analysis of compounds from the **World Drugs Index database**, aimed at identifying features that were important in making a drug orally active. It was found that the factors concerned involved numbers that are multiples of 5:
 - 1) a molecular weight less than 500
 - 2) no more than 5 hydrogen bond donor groups
 - 3) no more than 10 hydrogen bond acceptor groups
 - 4) a calculated log P value less than +5

Absorption



Log P : partitioning Coefficient.

نقصدها



* $\text{Log } p < 0.5$ highly Hydrophilic (good solubility ... poor Absorption).

* $\text{Log } p > 5$ highly Hydrophobic (poor solubility ... Low Absorption).

so: if $\text{Log } p$ less than 0.5 or more than 5 = bad for absorption.

* The optimum absorption \Rightarrow $\text{Log } p$ around 2

* In General:

لما يكون $\text{Log } p = 2$ يعني رح يجبر BBB وابدويتنا ما بنفضلها الشيء

يعتبر side effect، مهان صيغ اددويتنا بنحاول يكون $\text{Log } p$ قاعها بجيد عن 2

* molecular weight:

C:12 O:16 N:14
F:19 H:1 S:32

* H-bond donor & H-bond acceptor:

HBD


HBA

HBD: functional group contains (H) atom...

HBA: functional group contains lone pair of electron (..)

لحتى يستقبل البروتون H+

EX1: R-O-H




HBD? or HBA?



لحتى تكون HBD لازم يكون في عندي ... (e- deficient)


وقد وجد بالتالي



وبنفس الوقت أنا في عندي:



stable lone pair of e- in (O) atom
so: it act as HBA

EX2: -1 Amide-



HBD? HBA? or both?

تذكير:



عندها lone pair e- والسؤال الذي يتبعه هل هما local & Zed؟ والجواب لا؛ لأنهم داخلين ... resonance!

They are not available all the time...

so:

not HBA!

والآن بنشوف في عننا (H) وكمان في عندي e- deficient لأنو

N = electronegative atom
N <-> H


so:

it is HBD..

* ملحوظة على الهماس:




Localized يعني الإلكترونات موجودة على الذرة طول الوقت...

EX3: -3° Amide-



(N) هون ما عندها
Localized e⁻
بالتالي مرّة ثانية
ليست HBA
والآن لو شغنا فهي لا تمتلك H
وبالتالي ما رح تكون HBD ...
HBDx HBAx


Ex:



Ex4: -Ether-



heteroatom + Localized e⁻ + NO (H) atom
= HBA ✓




.the hybridization of (N) atom = sp²


. Allylic

* و كأنها صارت زي (O) عندها
resonance واحد يدخل
... localized والتالي

EX5: -ester-




كلاهما = HBA ✓




note:

(N) atom in Amide = 1 Lone pair of e⁻
(O) here = 2 Lone pair of e⁻





→ Histidine / amino acid :




($\ddot{N}=\text{C}$); allylic : HBA ✓ → $\ddot{N}=\text{C}$

($\text{N}-\text{C}$); HBD

→ Theobromine :



- **Lipinski's rule of five**
- The rule of five has been an extremely useful rule of thumb for many years, but it is neither quantitative nor foolproof. For example, orally active drugs such as atorvastatin, rosuvastatin, cyclosporin and vinorelbine do not obey the rule of five.




Vinorelbine

- الفيديوهات القصيرة (2) -

- The compounds that fall outside of Lipinski's rules :


ATORVASTATIN



- لازم يكون أقل أوي ساوي 500 -


- **MW – 559 g/mol**
- **HBA – 6**
- **HBD – 4**
- **log P – 6.36** - لازم يكون أقل أوي ساوي 5
- **F – 14%**

safe ✓ : ومع ذلك
effective ✓



venetoclax

- **MW – 868 g/mol** *huge!*
- HBA – 9
- HBD – 3
- **clog P – 6.12**
- F – 5.4%



montelukast

- **MW – 586 g/mol**
- HBA – 4
- HBD – 2
- **clog P – 7.20**
- F – 68%

parameter
ثاني غير
Lipinski's rule.

Physiochemical Factors Affecting Drug Absorption

- Work carried out by **Veber** in 2002, demonstrated the rather surprising finding that **molecular flexibility** (as measured by the number of freely rotatable bonds present in the structure) plays an important role in oral bioavailability.
- **The more flexible the molecule, the less likely it is to be orally active.** Less surprisingly, the analysis showed that the **polar surface area** of the molecule could be used as a factor instead of the number of hydrogen bonding groups.
- These findings led to the following parameters for acceptable oral activity. Either:
 - a polar surface area $\leq 140 \text{ \AA}^2$ and ≤ 10 rotatable bonds, or
 - ≤ 12 hydrogen bond donors and acceptors in total and ≤ 10 rotatable bonds.

• The more flexible the molecule, the less likely it is to be orally active...

• The veber rules:

→ polar surface area $\leq 140 \text{ \AA}^2$

&

rotatable bonds ≤ 10


OR

→ HBD + HBA ≤ 12

&

rotatable bonds ≤ 10

• Doxorubicin, has very low oral bioavailability.



Lipinski Rules

- H-bond donors = 7 **HBD > 5!**
- MW = 543 **MW > 500!**
- ClogP = -1.7 ✓ okay
- H-bond acceptors = 12 **HBA > 10!**

Veber Rules

- Rotatable bonds = 11 **R.b > 10!**
- PSA = 206 **pSA > 140!**
- Total H-bonds = 19 **Total > 12!**

* المعايير الصحيحة :

- HBD ≤ 5 ✓
- MW ≤ 500 ✓
- log p ≤ 5 ✓
- HBA ≤ 10 ✓


* المعايير الصحيحة :

- Rotatable bonds ≤ 10
- polar surface area ≤ 140
- HBD + HBA ≤ 12

Doxorubicin
تجاوز 3 rules !!


Doxorubicin
تجاوز كل Veber rules !!

لذلك
has v. Low oral bioavailability



Potency = 2 μ M

HBD = 0
HBA = 3
MW = 369 ✓
Log P = 5.7 ✗
PSA = 17
Rotatable bonds = 6



Potency = 1 nM
Poor oral absorption

HBD = 1
HBA = 6
MW = 591
Log P = 7.3
PSA = 50
Rotatable bonds = 14
Total HB = 6

Structural modification for the compound on the left were made to enhance activity, however, the new compound has better potency but poor bioavailability, a pitfall that could be avoided if lipinski and veber rules were predicted prior to synthesis.

• كان الهدف من التعديل لتحسين الفعالية والتعديل فعلاً زادها لكن قلل من bioavailability!

⇒ After modification { * better potency ✓ poor bioavailability very low absorption ✓